Monitor for any future amendments that could indicate a shift from passive to active intent, or for additional 13G filings by other institutional holders that would increase the known institutional overhang.
SION drugs
SION drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $3.57entry
- T+1 · 7d ago +3.64%α +4.01% · $3.70
- T+5 · 20h ago −12.61%α −10.91% · $3.12
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC disclosed a 5.8% passive stake in Sionna Therapeutics via a Schedule 13G filing. The stake of 2,639,418 shares was held as of September 30, 2026, and the filing certifies passive intent with no aim to influence control.
Key Financial Metrics
Key Facts
- Goldman Sachs Group and Goldman Sachs & Co. LLC filed a Schedule 13G disclosing beneficial ownership of 2,639,418 shares of Sionna Therapeutics common stock.
- The stake represents 5.8% of shares outstanding as of September 30, 2026.
- The filing certifies the securities were acquired and held in the ordinary course of business, not to change or influence control.
- This is a new 13G filing by Goldman Sachs; no prior 13G from this filer appears in the cross-filing context.
Financial Impact
2,639,418 shares, 5.8% of outstanding, valued at approximately $8.6M based on $148M market cap
Risk Factors
- Goldman Sachs may trade around this position; the 13G does not lock in the stake size.
- A 5.8% stake is below the threshold that typically triggers activist attention, but any future increase above 10% could draw more scrutiny.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000886982-26-000564 |
| Document: 0000886982-26-000564-index-headers.html | 0000886982-26-000564 |
| Document: 0000886982-26-000564-index.html | 0000886982-26-000564 |
| Document: 0000886982-26-000564.txt | 0000886982-26-000564 |
Track record
22 reports on SION
7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +89.29% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $3.70 Now $3.12 −15.68% settles Nov 17
- Nov 9, 20267d ago SC 13G Neutral 3/10 Viewing Entry $3.57 to $3.12 Now $3.12 −12.61% ▼ −12.61% −10.91% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $3.65 to $3.70 Now $3.12 −14.52% ▲ +1.37% +1.96% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $6.02 to $5.15 Now $3.12 −48.17% ▼ −14.45% −13.26% vs SPY
- Sep 21, 20268w ago SC 13D/A Bearish 7/10 Entry $6.02 to $5.15 Now $3.12 +48.17% ▲ +14.45% +13.26% vs SPY
- Sep 17, 20268w ago 144 Bearish 5/10 Entry $5.96 to $5.23 Now $3.12 +47.65% ▲ +12.25% +13.52% vs SPY
- Aug 10, 202614w ago 8-K Bearish 7/10 Entry $4.50 to $5.91 Now $3.12 +30.67% ▼ −31.33% −31.38% vs SPY
- Aug 6, 202614w ago 8-K Neutral 4/10 Entry $49.61 to $6.54 Now $3.12 −93.71% ▼ −86.82% −88.03% vs SPY
- Jul 9, 202618w ago Insider Cluster Neutral 4/10 Entry $45.29 to $45.29 Now $3.12 −93.11% · 0.00% +0.56% vs SPY
- Jul 9, 202618w ago Insider Cluster Bearish 5/10 Entry $45.29 to $45.29 Now $3.12 +93.11% · 0.00% −0.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers